Cost of hospital antimicrobial chemotherapy : A method for global calculation by Gyssens, I.C. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/14867
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
A R T I C L E S
Cost of hospital antimicrobial chemotherapy
A method for global cost calculation
Inge C. Gyssens, Christianne A. Lennards, YechielA . Hekster and  Jos W.M. Van derM eer
Introduction
The true cost of health care is what health care 
consumes of society’s resources. Under a tra­
ditional medical system, hospital costs (i.e. con­
sumption of hospital services such as those pro­
vided by the pharmacy and laboratory) are 
passed on to the patient or third-party payers 
and generate revenues for the hospital, contrib­
uting to the inflationary spiral in health care 
costs.
In general hospitals in the Netherlands, the 
current budget system was introduced in 1983 
and university hospitals followed in 1984. These 
budgets are based on a hospital’s consumption of 
resources during the year 1982 for general hospi­
tals and 1983 for university hospitals. In this 
budget system, it has become of primary import­
ance to contain internal costs since the Govern­
ment has limited hospital costs in an external 
budget. In 1988, a function-directed budget 
system was introduced for general hospitals [1].
A significant portion of a hospital’s total oper­
ating budget consists of drug purchases. As in 
the prospective payment system which is used in 
the United States (i.e. reimbursment categorized 
according to diagnosis-related groups), drug costs 
for in-patients generate no revenues. Antimi­
crobial drugs account for the largest proportion 
of all drugs, ranging from 13 to 37% of these pur­
chases by hospitals in a European study [2]. 
However, the true cost of antimicrobial therapy 
for the institution involves considerably more 
than the purchase cost of the drug employed [3]. 
The recognition that some drugs, which are very 
inexpensive to purchase, are expensive to use 
prompted the development of methods to esti­
mate the global cost of antimicrobial chemo­
therapy [4-6].
We performed a cost-identification analysis as 
described by Eisenberg [7], during a review of 
antimicrobial drugs usage evaluation. We ap­
plied a method for global cost calculation which 
takes into account acquisition costs, adminis­
tration and preparation costs, and monitoring 
costs in our hospital [8]. We subsequently con­
structed a cost-calculation system which quan­
tifies the cost difference for each route and each 
intravenous system of antimicrobial drug admin­
istration. The method permits comparison of the 
cost of actual and alternative antimicrobial drug 
policies in the quality-of-use review.
Methods
During a review of antimicrobial drug use 
evaluation in the 948-bed University Hospital of 
Nijmegen (the Netherlands), cost parameters 
were determined for the following components of 
antimicrobial chemotherapy of in-patients: anti­
microbial drug purchase costs, clerical costs, 
costs to prepare and administer the drugs and 
costs to monitor the drugs. The various cost com­
ponents were arranged in a spreadsheet, which 
permits calculation of the global cost per dose.
Purchase costs
The prices on the official wholesale price-list 
“Groothandelsprijslijst Courant Brocacef 1990” 
were chosen to determine the acquisition cost of 
antimicrobial drugs, instead of the contract 
prices of the hospital. Contract prices tend to 
vary between hospitals, reflecting the insti­
tution’s antibiotic and purchase policy. The true
K eywords
Antibiotics
Cost and cost analysis 
Drug utilization 
Financial management 
Hospitals
Infusions, intravenous
I.C. Gyssens (correspondence) and 
J.W.M. Van der Meer: 
Department of Internal Medicine, 
University Hospital Nijmegen, 
P.O. Box 9101, 6500 HB 
Nijmegen, the Netherlands.
C.A. Lennards:  Economic and 
Financial Department,
University Hospital Nijmegen. 
Y.A. Hekster: Department of 
Clinical Pharmacy, University 
Hospital Nijmegen.
Gyssens IC, Lennards CA, Hekster YA, Van der Meer JWM. Cost of hospital antimicrobial 
chemotherapy. A method for global cost calculation. Pharm Weekbl [Sci] 1991;13(6):248-53.
Abstract
We will describe the method of cost-identification analysis, which was performed in a 
Dutch hospital during a review of antimicrobial drugs usage. In the present Dutch hospital 
budget system, in-patients’ drug costs generate no revenues. Efforts to diminish drug costs 
result in financial benefit for the institution. To maximize cost containment, efforts are to be 
directed to all cost components. We chose wholesale purchase prices of antimicrobial drugs 
and national prices for salaries and hospital costs. Global cost comparison shows the most 
cost effective system of intravenous administration. Push injection is the most economic way 
to administer intravenous drugs which do not require dilution or prolonged infusion time. 
For stable solutions, such as metronidazole, ready-to-infuse bags are the most economic 
system. A global cost calculation is listed for commonly used antimicrobial drugs for 
in-patients. A cost comparison is given for vancomycin CP and teicoplanin, two 
antistaphyloccocal drugs, which are probably equieffective. The result of global cost 
comparison contributes to the decision to include new drugs into the hospital formulary or to 
replace older ones.
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acquisition costs of antimicrobial drugs in hos­
pitals are, in general, below the wholesale price. 
However, the invoice prices of drugs include ad­
ditional 6% taxes.
Cler'ical costs
Antimicrobial drugs listed in the hospital for­
mulary are kept in stock in the wards. For formu­
lary drugs, clerical costs per dose were deter­
mined by the labour time of nurses filling out the 
patient’s medication sheet. In case of nonfor­
mulary drugs, extra time was needed to obtain 
individual receipts from the treating physician.
Costs to prepare and  adm inister  drugs
Only the time of nurses was taken into ac­
count, since pharmacists were not involved in 
the preparation of admixtures for injection, and 
formulary drugs were kept in stock in the wards.
Oral administration, intravenous push (bolus) 
injection, intravenous piggyback (quick, small- 
volume infusion) and intermittent intravenous 
infusion (large volumes up to 500 ml, requiring 
30 min or more) were studied for cost compari­
son. Intramuscular injections were rarely used 
for antimicrobial drug administration in hospi­
talized patients.
Most intravenously administered antimicro­
bial drugs had to be reconstituted with sterile
water from powder vials as in the case of cepha­
losporins and penicillins. Some manufacturers 
provide dilution fluid as is the case for teicopla- 
nin. Ampoules contain a high concentration of 
antibiotic solution like gentamicin marketed as 
Garamycine®. Reconstituted vials were either 
injected with the help of a 20 ml syringe (push) 
into the tubing, or were injected in a piggyback 
or into a large-volume infusion bag for inter­
mittent infusion when dilution was required, e.g. 
clindamycin marketed as Dalacin®.
The direct costs associated with antimicrobial 
drug administration were broken down into per­
sonnel time and supplies. A questionnaire was 
given to the senior nurses of two wards. They 
were asked to collect several (minimum three) 
time measurements from their staff for all the 
components of oral and intravenous antimi­
crobial drugs administration. The nurses noted 
the time required with the help of a wristwatch. 
Subsequently, the senior nurses were inter­
viewed. Surveillance time of the intravenous 
intermittent infusions was estimated for dur­
ation of infusions (30, 60, 120 and 240 min). Both 
measurements and experience data were used to 
deduce mean administration time. Personnel 
time was multiplied by the average hourly wage 
for nurses to determine personnel costs.
System supply costs were also obtained from a
Table 1
Costs o f  antim  icrobial drugs (NLG)
Generic Brand Dosing Routed Whole­ Adminis­ Moni­ Global Global Wholesale
name schedule
(mg)
sale
cost/dose
tration
cost/dose
toring
cost/dose
cost/dose cost/day global cost
(%)
Benzyl­ Natrium  Pen G 1 MU/6 h i.v. push 1.30 5.80 0 7 28 18
penicillin i.v. infusion 1.30 8.80 0 10 40 13
Cefazolin Kefzol operating i.u. push 15.02 1.90 0 17 17 89
room i.v. infusion 15.02 5.80 0 21 21 72
1 x  1000
1,000/8 h i.u. push 15.02 5.80 0 21 62 72
i.v. infusion 15.02 8,80 0 24 71 63
Ceftazidime Fortum 1,000/8 h i.u. push 48.60 7.00 0 56 167 87
i.v. infusion 48.60 10.00 0 59 176 83
Cefuroxime Zinacef 750/8 h i.u. push 14.19 5.80 0 20 60 71
i.v. infusion 14.19 8.80 0 23 69 62
Clindamycin Dalacin C 300/6 h i.v. infusion 12.10 9.40 0 22 86 56
600/8 h i.v. infusion 24.20 10.60 0 35 104 70
Gentamicin Garamycin 120/12 h, 
< 72 h
i.u. infusion 19.80 7.70 0 28 55 72
120/12 h * i.v. infusion 19.80 7.70 6.30 34 68 59
Metroni­ Flagyl 2 x  250/8 h oral 1.20 0.60 0 2 5 67
dazole generic product operating
room
1 x  500
i.u. infusion 4.00 1.80 0 6 6 69
500/8 h i.v. infusion 4.00 3.60 0 8 23 53
Piperacillin Pipcil operating  
room 
1 x  4,000
i.v. infusion 46.55 5.80 0 52 52 89
Cipro­ Ciproxinj 500/12 h oral 6.22 0.90 0 7 14 87
floxacin 200/12 h i.v. infusion 69.51 3.90 0 73 147 95
* >  72 h or renal function impairment. 
fNonformulary drug, 
t  i.v.: intravenous.
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wholesale price-list. Similarly, contract prices of 
supplies are usually lower since large quantities 
are purchased. An additional 18.5% taxes are 
added in the invoice. Costs of personnel time and 
supplies were arranged in a separate spread­
sheet to allow calculation of the administration 
costs per dose for each system of administration.
M onitoring costs 
When an antimicrobial drug has a narrow ther­
apy versus toxicity range, additional laboratory 
tests are required to monitor drug concentrations 
in blood and organ function. For the calculation 
of the monitoring costs of aminoglycosides, we 
assumed that no extra laboratory tests were re­
quired during the first 72 h of treatment from 
patients with normal renal function and no 
haemodynamic instability [9]. However, patients 
presenting unstable circulation due to Gram- 
negative septicaemia, patients with burns, or 
patients who had impaired renal function re­
quired two extra measurements of creatinine 
and one set of aminoglycoside serum concen­
trations (peak and trough) a week for monitor­
ing. If treatment continued beyond 72 h, even in 
patients with normal renal function, similar ex­
tra laboratory tests were needed.
Since the real costs of laboratory tests are un­
known on a national level, laboratory cost calcu­
lations were based on cost approximation by the 
‘Spaander points’ system (national guidelines). 
This system takes into account total laboratory 
operating costs (laboratory staff wages, supplies, 
equipment, energy etc.). Each laboratory test is 
given a number of ‘Spaander points’ which re­
flects the relative contribution of the test to 
workload and its consumption of supplies. The to­
tal annual production by a laboratory is ex­
pressed in an amount o f ‘Spaander points.’ Divid­
ing the total production by the total operating 
costs results in a cost per ‘Spaander point,’ which
varies per laboratory. However, to allow cost 
comparison of laboratory tests on a national 
level, the average national cost per ‘Spaander 
point,’ based on national guidelines was used for 
calculations [10].
Results
Purchase costs 
The acquisition costs (wholesale price) per dose 
for commonly used antimicrobial drugs are listed 
in Table 1 (column 5).
Clerical costs 
A nurse’s clerical time per dose was considered 
a question of seconds for formulary drugs, and 
was not taken into account. However, nonformu- 
lary drugs took more time, i.e. an average of 
0.5 min per dose.
Costs to prepare and  adm in is ter  drugs  
The results of the nurse’s average time needed 
to reconstitute, prepare and administer formu­
lary drugs are shown in Table 2. Oral doses (tab­
lets or capsules) required 1 min. Total time for 
intravenous push injections ranged from 4.5 min 
to 8.5 min, depending on the complexity of re­
constitution. Reconstitution times varied from
1.5 to 4 min. To ease the calculations, we allo­
cated the antimicrobial drugs to two groups: nor­
mal reconstitution (mean 2 min) and difficult re­
constitution (mean 4 min).
The average time required for injection into 
tubing (push) was 4.5 min. Suspending an in­
fusion bag and connecting it to the patient’s 
intravenous device (intravenous infusion tubing  
or heparin-lock catheter), averaged 2 min. All 
antimicrobial drug infusions were regulated 
with the help of a rollerclamp. Total infusion 
times were according to the package insert. For 
surveillance of the infusion, 1 min extra time
Table 2
N u rse ’s time needed for reconstitution, preparation a nd  adm in is tra tion  o f  one dose o f  an antim icrobial  
drug
Route of 
administration
Nurse’s time (min) Total time
I  "1 /  / * i  n  I
reconstitution administration surveillance*
vmin/aose;
Oral 0 1 0 1
Intravenous 0 4.5 0 4.5
push 2 (normal) 4.5 0 6.5
4 (difficult) 4.5 0 8.5
Intravenous 0 2 1 ( 15) 3
infusion 2 ( 30) 4
4 ( 60) 6
2 (normal) 2 1 ( 15) 5
2 ( 30) 6
4 ( 60) 8
10 (240) 14
4 (difficult) 2 1 ( 15) 7
2 ( 30) 8
4 ( 60) 10
^Infusion time in parentheses; 1 min surveillance time per 15 min infusion time up to 60 min, then
1 min surveillance time per 30 min infusion time.
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Table 3
Costs o f  intravenous supplies per dose (NLG)
Supplies Method of administration
push injection infusion/piggyback infusion/intermittent infusion/bag
Syringe 5 ml 0.32 0.32 0.32 —
Syringe 20 ml 0.69 — - —
Needles 0.32 0.32 0.32 —
Gauze, disinfectant 0.07 0.06 0.06 0.10
Aqua distillata 0 .5 0* /- 0 .50 * /- — —
Infusion bag (50-500 ml) - 2.90 2.90 —
Y site - 1.70 1.70 1.70
Total 1.90*/1.40 5.80*/5.30 5.30 1.80
'^Reconstitution fluid needed.
T able  4
Costs to prepare and  adm in is ter  teicoplan in and  vancomycin  <CP
Generic name Route Dosing Time Time* Supplies Administration
schedule (min) cost cost cost/dose
(mg) (NLG) (NLG) (NLG)
Teicoplanin intravenous push 400/24 h 13.50 8.10 1.40 9.50
Vancomycin CP intravenous infusion 1,000/12 h 11.00 6.60 5.80 12.40
*The cost of a nurse’s minute is NLG 0.60.
was needed for 15 min infusion time, up to a total 
of 4 min for 1-h infusion time. Intravenous anti­
microbials which took 2 h infusion time (vanco­
mycin CP 1 g) and 4-6 h infusion time (ampho­
tericin B) scored 2 min/h extra.
The calculated cost of a nurse’s minute was 
NLG 0.60 in 1990, based upon factual nursing 
costs of this hospital.
The supplies and associated cost (disinfection) 
needed for all procedures are listed in Table 3. As 
an illustrative example, the comparison between 
the costs to prepare and administer teicoplanin 
and vancomycin CP is shown in Table 4. For tei­
coplanin and vancomycin CP, the exact measure­
ments for preparation and administration time
T able  5
Costs o f  laboratory tests for antim icrobial drug  
m onitoring  (NLG)
Test ‘Spaander points’* Cost
Leukocytes 2 2.72
Creatinine 5 6.80
Potassium 5 6.80
Aspartate amino­
transferase 8 10.88
S eru m  concentration
Gentamicin 20 37.40
Vancomycin 35 65.45
*‘Spaander points’ of the chemistry laboratory 
NLG 1.36; ‘Spaander points’ of the bacteriology 
laboratory NLG 1.87.
are used. Reconstitution of a single vial required 
3 min for both drugs. Since teicoplanin was 
manufactured in vials of 200 mg, for the reconsti­
tution of teicoplanin 400 mg, 6 min were needed. 
For injection of teicoplanin, 7.5 min were needed, 
due to the production of foam when nurses auto­
matically shaked the vial during the reconsti­
tution process.
M onitoring costs 
Laboratory costs are listed in Table 5. Monitor­
ing aminoglycosides, such as gentamicin, raised 
the weekly treatment costs by NLG 88.40. This 
amount was due to serum creatinine measure­
ment, NLG 6.80, twice a week + one aminoglyco­
side serum peak and trough concentration, 
NLG 74.80. In a dosing schedule of gentamicin  
twice daily the additional monitoring cost/dose 
was NLG 6.30. Similar monitoring of vancomy­
cin CP amounted to NLG 144 a week. When 
audiometry was performed, as advised in case of 
prolonged administration by the package insert, 
the weekly costs were NLG 174 or NLG 12.40 
per dose (twice daily dosing). The package insert 
of teicoplanin advises to monitor renal and audi­
tory function in patients with renal function im­
pairment or prolonged administration, without 
measurement of serum concentrations. These 
costs amounted to NLG 44 per week or NLG 6 
per dose. Serum (trough) concentrations were 
only considered meaningful for monitoring effi­
cacy. The cost of a serum concentration of teico­
planin was NLG 65.45. Laboratory costs per dose 
for vancomycin and teicoplanin are listed in 
Table 6.
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Table 6
Cost cotnparison o f  vancomycin CP and  teicoplanin (NLG)
Generic name Brand Dosing 
schedule (mg)
Routet Wholesale Administration Monitoring Global 
cost/dose cost/dose cost/dose cost/dose
Global
cost/week
Teicoplanin Targocid 400/24 h* i.v. push 250.02 9.50 0 259 2,072*
400/24 h i.v. push 250.02 9.50 6.00 265 1,855
Vancomycin Vancocin CP 1,000/12 h i.v. infusion 119.06 12.40 0 131 1,834
1,000/12 h i.v. infusion 119.06 12.40 12.40 143 2,007
*First week; including 1 loading dose prolonged administration 
ti.v.: intravenous.
Global costs
The resulting global costs of common antimi­
crobial drugs are listed in Table 1. The most 
economic systems of intravenous administration 
are printed in italics (a complete list can be ob­
tained from the authors upon request). As an 
illustrative example, global cost comparison 
between a formulary antimicrobial drug (van­
comycin CP) and a newly marketed antimicro­
bial drug with similar efficacy (teicoplanin) is 
shown in Table 6. For teicoplanin, at least one 
loading dose is needed to rapidly achieve steady- 
state concentrations [11]. For the first week of 
treatment with teicoplanin, the costs per week 
are the result of eight doses.
D iscussion
In a cost-identification analysis of hospital 
antimicrobial drug therapy, the computer 
spreadsheet technique permits quick calculation 
if values of the cost components change, such as 
purchase prices or nurse’s wages.
Sinces purchase contracts differ between hospi­
tals due to competitive bidding or quantity of 
drug purchased, wholesale prices were preferred 
to allow objective comparison between drugs on 
a national level. The contract acquisition price of 
an antimicrobial drug which is commonly used 
in an institution can be as low as 25% of its of­
ficial wholesale price. However, this situation is 
rather exceptional, and it exists only for a few 
older drugs. The acquisition cost of most anti­
microbial drugs is-about 10% lower than the of­
ficial price after taxes.
We did not take into account pharmacy hand­
ling costs. Pharmacy distribution costs vary with 
the logistic organization of drug distribution 
within the hospital. Steenhoek combined phar­
macy and nurse handling costs in his cost com­
parison of antibiotic therapies [1].
The present cost calculation points out the 
most economic way and system to administer 
intravenous antimicrobial drugs. Different cost 
components seem relatively important for differ­
ent drugs. The administration costs of benzyl- 
penicillin 1 MU intravenously represent 83 to 
88% of the global cost per dose and intravenous 
push injection is 30% less expensive than intra­
venous piggyback infusion (Table 1). When the 
predominant cost element is the acquisition cost 
of the drug (vancomycin CP, teicoplanin), the 
proportional savings by changes in the system of 
administration (intravenous push or intermit­
tent infusion) and dosing schedule seem negli­
gible (Table 6). However, administration costs of 
intravenous piggyback infusions (generally 
NLG 8.80) are almost always larger than those of 
intravenous push injection (generally NLG 5.80), 
as shown for benzylpenicillin and cefazolin in 
Table 1. The infusion bag (50 to 500 ml) accounts 
for most of the cost difference between both sys­
tems. Thus, push injection invariably saves a 
fixed amount of money per dose of drug which 
does not require dilution or prolonged infusion.
Although in some Dutch hospitals nurses are 
not authorized to perform injections into intra­
venous tubing or intravenous catheters, the re­
ports of the committee on responsibility of nurses 
in general hospitals advise the same code of 
authorization for the medical acts of intravenous 
infusion and intravenous injection [12 13]. More­
over, push injection has increased security since 
rapidly occurring side-effects are noted earlier. 
Thus, both for safety reasons and from a cost-con- 
tainment point of view, intravenous push injec­
tion (3-5 min) is preferable to short-term 
(< 1 5  min) piggyback infusion. Intermittent in­
fusion (large volumes, requiring more than 
30 min) should be reserved for drugs that require 
dilution or a prolonged infusion time, such as 
vancomycin or amphotericin B.
For stable solutions, ready-to-infuse bags are 
the most economic system for intermittent ad­
ministration (metronidazole) (Table 1). Teico­
planin has the advantage over vancomycin CP 
that it can be administered by push injection. 
However, by inadvertence, the production of 
foam during reconstitution can add several 
minutes to the subsequent injection and savings 
are less than one would expect (Table 5).
Another strategy of antimicrobial drug admin­
istration which can save time of nurses and sup­
plies is illustrated in surgical prophylaxis. All 
anaesthesiologists in our hospital preferred to 
administer cefazolin by push injection [Gyssens 
IC, unpublished observations]. On the other 
hand, nurses in surgical wards almost invariably 
administered cefazolin in piggyback. The cost of 
one dose of cefazolin for peri-operative prophy­
laxis given by the anaesthesiologist in the oper­
ating theatre is NLG 17. The same dose admin­
istered preoperatively on the ward by a nurse 
amounts to NLG 21. Both calculations are shown 
in Table 1.
The cost of aminoglycosides rises by NLG 6.30 
per dose (twice daily dosing) after 72 h when
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monitoring becomes a necessity. Aminoglyco­
sides are much less expensive when used in em­
piric therapy for synergy and broadening of the 
spectrum during the first days before culture re­
sults become known. Monitoring costs can be 
avoided by replacing empirically given amino­
glycosides by less toxic antimicrobial drugs in 
subsequent documented therapy.
From Table 1 it is clear that single-dose 
prophylaxis with a combination of antimicrobial 
drugs is not always more expensive than prophy­
laxis with one drug. For example, peri-operative 
prophylaxis with one dose of piperacillin 
(NLG 52) is more than twice as expensive as the 
combination of cefazolin with metronidazole
(NLG 23).
The global cost per day (Table 1) or per week 
(Table 6) should be considered for cost compari­
son between drugs, since the daily cost of anti­
microbial therapy can be largely influenced by 
differences in dosing schedules and monitoring.
We did not include complication costs in our 
calculation system. To our knowledge, there are 
no European data on the subject. Figures from 
the United States are irrelevant for the 
European situation as they are largely in­
fluenced by litigation costs. Still, we feel that for 
antimicrobial drugs with established renal and 
otovestibular toxicity, such as the aminoglyco­
sides, a certain amount of money has to be added 
to obtain the true global cost of these drugs. This 
is a reason to try and replace toxic antimicrobial 
drugs from the formulary by less toxic, equief- 
fective ones. Global cost considerations should 
guide decisions to introduce new drugs for the 
hospital formulary rather than purchase costs of 
antimicrobial drugs.
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